Japanese and European generics groups have met to discuss increase regulatory cooperation between the two regions.
Europe–Japan cooperation on generics and biosimilars regulation
Home/Policies & Legislation
|
Posted 06/06/2014
0
Post your comment

The Japanese Generic Medicines Association (JGA), the Nippon Keidanren (Japanese Industry Association), the European Generics medicines Association (EGA) and the European Union (EU) Delegation to Japan met in March/April 2014 to promote regulatory cooperation on generics and biosimilars as part of the EU–Japan free trade negotiations.
According to EGA, Japan and the EU share similar objectives to promote generics and biosimilars as key components of sustainable healthcare models. The association is therefore supporting efforts to improve regulatory cooperation in this field. In particular, they are focused on the single development for the approval of biosimilars and complex specialty generics to avoid the unethical duplication of clinical studies. While another area of importance is the mutual recognition of good manufacturing practice (GMP) inspections to reduce duplicative inspections.
According to Mr Adrian van den Hoven, Director General of EGA, ‘Japan is facing an increasing demand for health care due to its ageing population. Regulatory cooperation with the EU will help Japan reach its generic medicines targets and will increase the use of biosimilar medicines making healthcare more sustainable for Japan and for patients.’
The EU–Japan negotiations for a Free Trade Agreement were officially launched on 25 March 2013. Until now five negotiating rounds have taken place (in April, June, and October 2013 and in January and March/April 2014). Japan is the EU’s second biggest trading partner in Asia, after China. Together the EU and Japan account for more than a third of the world’s gross domestic product (GDP).
Related articles
EGA calls for removal of competition and trade barriers for generics
Pharmaceutical trade barriers are falling
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.
Source: EGA, Europa
Guidelines
Canada poised to remove requirement for Phase III trials for biosimilars
European position paper on AI in medicinal product lifecycle
Reports
Regulating biosimilars in Argentina: ANMAT’s approach
China-to-West pharma licensing deals surge in 2024 amid innovation push
DIGEMID’s 45-day auto-approvals trigger safety warning

Home/Policies & Legislation Posted 30/06/2025
ANVISA and Danish Medicines Agency renew health regulatory collaboration

Home/Policies & Legislation Posted 06/05/2025
Colombia and Brazil introduce reforms to enhance healthcare regulation

Home/Policies & Legislation Posted 22/04/2025
Second wave of drugs selected for Medicare price negotiation

Home/Policies & Legislation Posted 11/04/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment